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Stem  cell  biology  has  captured  the  imagination  of 
biologists,  tissue  engineers,  pharmaceutical  company 
scientists, and indeed the general public, largely because 
of the prospect it seems to offer of manipulating cell fate 
to treat disorders for which there is no other effective 
therapy.
The initial focus was on diseases like type 1 diabetes 
and  Parkinson’s  disease  (PD),  in  which  attempts  had 
already been made to treat patients with donor cells [1,2]; 
but it was quickly recognized that embryonic stem cell 
(ESC) behavior may not be easy to control, and develop­
ing cells as safe and effective products is not as straight­
forward as developing small molecule or protein­based 
drugs, for which a great deal of experience has accumu­
lated.  The  case  of  Geron,  the  biotechnology  company 
that has been the first to initiate a clinical trial using ESC­
derived cells, illustrates the hazards of developing a cell­
based  product  [3].  This  led  to  efforts  to  use  stem  cell 
biology to identify and develop small molecule drugs to 
target endogenous stem cell populations — for example, 
to stimulate neurogenesis to treat stroke, traumatic brain 
damage, Alzheimer’s disease (AD) or PD, or other dis­
orders of mood or cognition [4], or to inhibit stem cell­
like cells in solid tumors [5].
In this review, we will focus on a variant of that idea: 
the use of human pluripotent cells in culture to produce 
differentiated cells that can be used as models on which 
to screen new drugs. One motivation for this is the wide­
spread  recognition  that  the  drug  discovery  process  as 
practiced  in  most  pharmaceutical  companies  is  ineffi­
cient, at best, and, in the past decade or so, has struggled 
to meet the need for new drugs. In addition, there have 
been a number of famous cases in which already marketed 
drugs have been found to have unanticipated side effects. 
Standard preclinical drug safety testing relies exclusively 
on  administering  drugs  to  two  non­human  animal 
species, and it is possible that safety studies on validated 
human cells might help avoid unexpected drug toxicities.
Three key advances
From our perspective, the interest in stem cell biology as 
a  route  to  novel  therapeutic  drugs  arose  from  the 
convergence of three separate lines of investigation. First 
there is evidence that pathways that regulate embryonic 
development and, hence, act in large part on tissue stem 
and progenitor cells are also disrupted in adult disease 
[6,7].  For  example,  the  hedgehog  signaling  pathway,  of 
vital  importance  in  nervous  system  development,  is 
hyper  activated  either  by  mutation  or  by  ligand  over­
expression in a significant percentage of human cancers 
[8].  More  than  10  years  ago,  we  showed  that  it  was 
possible to identify drug­like small molecules that inhibit 
hedgehog  signaling  and  are  effective  in  various  cancer 
models [9,10], bringing together the worlds of develop­
mental biology and conventional drug identification. In 
fact, as recently presented at the American Association 
for Cancer Research meeting by Dr Ervin H Epstein, a 
derivative  of  the  first  hedgehog  antagonist  developed, 
vismodegib, has been shown to have positive results in a 
phase II clinical study for metastatic basal cell carcinoma. 
Other  hedgehog  antagonists  have  already  entered  the 
clinic,  including  several  developed  by  major  pharma­
ceutical companies [11]. The observation that there is a 
link between stem cells, their regulatory pathways, and 
disease  has  clearly  piqued  the  interest  of  the  pharma­
ceutical industry, and there is serious interest in develop­
ing  modulators  of  other  pathways,  such  as  Wnt  and 
Notch, that are active in the embryo.
The second trend followed from a seminal discovery 
made by Jessell and co­workers [12] on the specification 
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http://www.biomedcentral.com/1741-7007/9/42of  motor  neurons  and  other  neurons  in  developing 
mouse spinal cord. They established a key role for sonic 
hedgehog­regulated signaling, and went on to show that 
the differentiation of motor neurons could be recapitu­
lated in culture by adding retinoic acid to mouse ESCs to 
generate spinal cord progenitors and then an activator of 
the  hedgehog  pathway  [12].  That  was  achieved  with  a 
small molecule that potently activates hedgehog signaling 
[13]. The lessons learned from this study were that: (a) it 
is  possible,  at  least  some  of  the  time,  to  control 
differentiation of ESCs; (b) small molecules that regulate 
differentiation can be found; (c) by correctly controlling 
properties of stem and progenitor cells, it is possible to 
contemplate making large numbers of a defined type of 
cell. This work also opened up the possibility of making 
large  numbers  of  differentiated  cells  from  mice  engi­
neered to express human disease genes.
The  third  major  advance  was  the  reprogramming  of 
adult  cells  to  induced  pluripotent  stem  cells  (iPSCs), 
described  by  Yamanaka  and  co­workers  [14,15].  The 
discovery that differentiated cells ­ for example, dermal 
fibroblasts — could be induced to revert to a pluripotent 
state made it possible to avoid both the political and the 
practical  difficulty  of  using  human  ESCs,  of  which 
supplies are limited. iPSC technology offers the prospect 
of capturing cells derived from a large number of specific 
types of pre­diagnosed adult patients, potentially at any 
age, and a correspondingly large number of controls in a 
format that can support an industrial level of screening, 
efficacy, and safety studies.
Stem cells as a tool for drug research and 
development
Stem  cell  biology  is  a  rapidly  growing  field,  and  many 
excellent reviews of some of the topics covered here are 
available. In this article, we focus on using stem cells for 
drug research and development.
The central concept is that stem cells can provide a new 
means  of  studying  the  pathological  basis  of  disease, 
screening for drug leads, testing candidate drug efficacy 
and safety, and selecting patient populations for clinical 
testing. The plan would be to identify a disease of interest 
and  obtain  skin  biopsies  or  other  tissue  samples  from 
patients with that disease. For each patient, iPSCs would 
be generated, expanded and (re)differentiated to the type 
of  cells  most  affected  in  the  disease  of  interest  —  for 
example, motor neurons for amyotrophic lateral sclerosis 
(ALS) or spinal muscular atrophy (SMA) — and to those 
most  commonly  affected  by  drug  side  effects  (cardiac 
myocytes and hepatocytes). Once appropriate studies on 
disease mechanisms had been completed, screens could 
be set up to discover drug leads capable of correcting the 
disease phenotype. These screens may be phenotypic; for 
example, for ALS, a motor neuron survival screen could 
be  appropriate.  Hit  compounds  would  be  pursued  by 
medicinal chemists (in the case of small molecule thera­
peutics)  in  the  traditional  way.  But  efficacy  would 
continue to be tested on human diseased cells, and safety 
would be assessed in a preliminary fashion using corres­
ponding cardiac and liver cells. Once potential lead com­
pounds were identified, they would be tested on a broad 
sampling  of  individual  patient­derived  diseased  cells, 
along with cardiac muscle and hepatocytes. This would 
aid in deciding whether certain compounds were more 
likely than others to be active across a large percentage of 
patients or, at a minimum, in preselecting the particular 
patients most likely to respond to a specific agent. The 
cost of drug discovery could be considerably reduced if a 
greater percentage of compounds entering the clinic were 
approved as drugs as a consequence of having better drug 
targets, better safety profiles, or a more considered choice 
of patient population.
How  can  we  decide  if  this  new  approach  can  really 
evolve into an improved system of discovering and test­
ing  new  drugs?  Ultimately,  the  answer  can  only  be 
provided  in  the  clinic,  and  that  will  take  a  long  time. 
How  ever, prior to that, we will need to establish tech­
niques to (a) produce patient­derived cells that are capable 
of multi­lineage differentiation; (b) regulate their differ­
en  tiation  into  disease­relevant  cell  types;  (c)  use  the 
differ  en  tiated  cells  to  learn  more  about  diseases  of 
interest; (d) carry out primary screens and other types of 
efficacy testing on those cells; (e) assess a small number 
of  the  best  compounds  against  a  large  sampling  of 
patient­specific  disease­relevant  cells.  These  steps  are 
explored in greater detail below.
Producing cells with broad differentiation 
potential: iPSCs
The original methods of adult cell reprogramming were 
based on the use of viral vectors that drive the expression 
of the four transcription factors — Oct3/4, Sox2, c­Myc 
and  Klf4  —  identified  by  Yamanaka  and  colleagues. 
However, at least one of these — c­myc — has oncogenic 
potential [14,15], and these methods are also subject to 
the risk of insertional mutagenesis. This has led to efforts 
to  produce  iPSCs  without  genome  modification.  Most 
recently, a great deal of interest has surrounded a new 
method of reprogramming that is based on the addition 
of synthetic mRNAs encoding the four Yamanaka trans­
cription factors [16].
At least some of the concerns associated with repro­
gram  ming  would  be  avoided  if  it  were  possible  to  re­
program  with  just  small  molecules  or  proteins,  and 
chemical biologists have also studied the reprogramming 
process. A large number of cocktails have been derived, 
all of which use different mixtures of small molecules and 
transduced genes (reviewed in [17]). The small molecules 
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reprogramming factors or have improved the efficiency 
of the overall process. Many of the screens have provided 
some  insight  into  the  mechanism  of  reprogramming. 
One  example  of  such  a  screen  was  based  on  a  simple 
experiment designed to identify a small molecule capable 
of  replacing  the  transcription  factor  Sox2  [18].  Mouse 
embryo  fibroblasts  were  transduced  with  retroviruses 
coding for Klf­4, Oct­4 and c­Myc, but not Sox2. Under 
those conditions, no true iPSC colonies formed. The cells 
were then treated with agents selected from an annotated 
compound  library  enriched  in  small  molecules  that 
modulate intracellular signaling. The most potent hit was 
an  inhibitor  of  transforming  growth  factor  (TGF)­β 
signal  ing. The surprise was in the way it acted: it increased 
expression  of  Nanog,  another  transcription  factor  with 
reprogramming activity. Furthermore, it affected not the 
starting  cell  population,  but  a  population  of  partially 
reprogrammed  intermediate  cells  that  appeared  1  to 
2 weeks after virus addition. This work, along with many 
other reports, demonstrates that reprogramming can be 
achieved in several, perhaps numerous, ways, with cells 
traversing  different  paths  of  dedifferentiation  via  many 
transient states of partial dedifferentiation. These repro­
gram  ming intermediates are, in a sense, artificial, being 
created as a result of an artificial process. This concept 
will be explored later in the context of regulating a real 
biological process: cell differentiation.
Disappointingly, at the time of writing, it has not been 
possible to reprogram cells completely with chemicals, 
although small molecules that replace individual trans­
cription  factors  have  been  found.  Is  this  because  it  is 
difficult  to  replace  the  activity  of  transcription  factors 
effectively  with  small  molecules?  That  may  be  true, 
although, as pointed out above, TGF­β inhibitors act by 
regulating the expression of a transcription factor. Is it 
because  it  is  difficult  to  find  combinations  of  small 
molecules that complement one another in the way that 
the transcription factors can? Is it just due to a lack of 
experimental  insight  into  how  best  to  replace  these 
particular transcription factors? Answering these ques­
tions  will  be  important  because  there  are  many  other 
circumstances, reviewed later, in which small molecule 
modulation of cell fate could be valuable.
How useful are iPSCs?
In  the  past  few  months,  a  spate  of  publications  have 
highlighted problems that might be inextricably linked to 
reprogramming itself, perhaps independent of the parti­
cu  lar  method  used  [19­22]  (reviewed  in  [23]).  These 
include defects related to mutations, gene copy number 
variation, and incomplete resetting of DNA methylation. 
Some of these abnormalities may persist in differentiated 
cells  produced  from  the  iPSCs;  some  may  be  selected 
against by repetitive passaging. It is probably fair to say 
that  iPSCs  will  be  difficult  to  use  therapeutically  until 
these issues are resolved.
In spite of this significant concern, iPSCs may still have 
significant  value  in  drug  discovery.  However,  in  that 
context, there is another potential problem. iPSC clones, 
even those prepared from a single patient, vary in their 
capacity to give rise to differentiated cells. Such variability 
has  been  seen  previously  with  human  ESC  lines  [24], 
which can show significant differences although they all 
meet  the  standard  criteria  for  ESCs.  That  is,  although 
they were all able to give rise to cells from the three germ 
layers in vitro and form teratomas in mice, some gave rise 
to  endodermal  lineages  well,  some  gave  rise  to  meso­
dermal  lineages  well,  and  so  on.  Thus,  the  standard 
criteria used to define pluripotency do not preclude line­
to­line variability.
In an attempt to provide a systematic basis for charac­
terizing stem cell lines, Bock and colleagues [25] carried 
out an extensive bioinformatics comparison of 20 human 
iPSC and 12 human ESC lines, including DNA methyla­
tion patterns, microarray analyses, and a general differen­
tiation assay in which gene expression was analyzed in 
embryoid bodies derived from each line. On the basis of 
these data, it was possible to distinguish an average iPSC 
line from an average ESC line, although there was also 
considerable overlap. Importantly, the authors developed 
a  scorecard  based  on  a  500­gene  expression  array  to 
quantify the differentiation tendencies of each line. The 
scorecard predicted that two of the iPSC lines might have 
reduced ability to differentiate into neurons and this was 
confirmed  experimentally  in  a  study  carried  out  by 
Boulting and colleagues [26], who, however, also showed 
that  most  iPSC  lines,  whether  derived  from  healthy 
controls  of  different  ages  and  sexes  or  from  different 
types of ALS patients, could be induced to differentiate 
adequately  into  motor  neurons.  This  suggests  that  the 
variability of the cell lines may not preclude their use in 
screening. What remains to be measured is the degree of 
variability in cell response to therapeutic candidates. Do 
motor  neurons  produced  from  several  different  iPSC 
lines, all from the same patient, have the same response 
to  potential  drugs?  Are  data  collected  from  motor 
neurons  derived  from  different  individuals  reliable 
enough to predict clinical responsiveness across patients? 
Information like this is essential for the approach being 
discussed  here.  It  will  also  be  essential  to  develop 
methods  for  reliably  inducing  the  various  types  of 
differentiated cells from stem cells. In that aim, there is 
good  alignment  between  scientists  interested  in  drug 
discovery  and  those  focused  on  regenerative  medicine 
(cell­based  therapy).  Thus,  there  is  a  real  need  to 
understand  how  to  produce  cells  that  are  sufficiently 
differentiated  to  (a)  model  pathological  aspects  of 
Rubin and Haston BMC Biology 2011, 9:42 
http://www.biomedcentral.com/1741-7007/9/42
Page 3 of 11disease; (b) faithfully predict drug safety; and (c) integrate 
effectively into tissue when transplanted.
Embryonic development in a dish
Recent studies aimed at producing specific differentiated 
cells  from  ESCs  or  iPSCs  have  followed  the  principle 
established by Wichterle and colleagues [12] and attemp­
ted to recapitulate embryonic development in cell culture. 
At  the  core  of  this  approach  is  the  recognition  that 
embryonic development occurs as a series of steps, with 
cells that have multipotential capacity becoming increas­
ingly differentiated (Figure 1). However, even armed with 
this recognition, success has been somewhat mixed.
One  instructive  example  is  that  of  Kattman  and 
colleagues  [27],  who  published  a  very  thorough  paper 
describing a protocol to produce cardiac myocytes from 
ESCs  and  iPSCs  in  which  they  sequentially  added 
morpho  genic  factors  important  in  the  appearance  of 
cardiac muscle. They stressed a few general conclusions: 
(a)  the  first  step  of  any  differentiation  procedure,  the 
induction  of  the  correct  germ  layer,  must  occur  effi  ci­
ently;  (b)  quantitative  markers  of  different  stages  of 
develop  ment are helpful; (c) the timing of activation or 
inhibition  of  various  morphogenic  pathways  is  critical, 
especially given that the very same pathway can have a 
stimulatory or an inhibitory influence at different times; 
and (d) the concentration of the inducing factors must be 
controlled carefully. In essence, this work confirms that 
the  complex  environment  of  the  embryo  can  be 
reproduced to at least some degree. However, the authors 
also pointed out that there is significant variation among 
different  cell  lines  so  that  protocols  may  have  to  be 
tailored  to  each,  perhaps  because  individual  lines  may 
make  variable  amounts  of  their  own  inducing  factors. 
This would be a significant hurdle if it were necessary to 
produce  cardiac  myocytes  from  tens  or  hundreds  of 
patient lines for drug toxicity testing. Thus, finding a way 
of overriding this variability would be a valuable advance.
Again by adopting an analogous strategy, Studer and 
colleagues  [28]  have  pursued  methods  for  producing 
parti  cular types of neurons efficiently. Importantly, they 
introduced a convenient way of regulating early neural 
induction  by  treating  human  ESCs,  grown  without 
standard feeder layers, with inhibitors of both TGF­β and 
bone morphogenetic protein (BMP) signaling [28]. This 
group went on to show the utility of this technique in the 
generation of dopaminergic neurons and motor neurons. 
Subsequent studies confirmed its utility in the derivation 
of cell types as diverse as neural crest [29] and floor plate 
[30].
Figure 1. The most common approach for regulating cell differentiation is based on coaxing cells through sequential stages of 
differentiation. The top schematic is generic and could be applied to any cell type. The lower paradigm is one that could be used to produce 
pancreatic β-cells and is taken from the work of Chen et al. [43]. DE, definitive endoderm; EP, endocrine progenitor; PP, pancreatic progenitor.
Directed Differentiation Screens: From ES Cell to Target 
Cells with Small Molecules
Factor 1
Factor 4
Factor 3
Embryonic stem cell (Oct4)
Progenitor 1 (Marker set 1)
Progenitor 2 (Marker set 2)
Specified cell
Progenitor 3 (Marker set 3)
Factor 2
A β-Cell Differentiation 
Paradigm
PDX
NGN
INS
ESC 
OCT4+
DE 
SOX17+
PP 
Pdx1+
EP 
NGN3+
Beta cell 
Insulin+
A generic stepwise 
differentiation paradigm
Rubin and Haston BMC Biology 2011, 9:42 
http://www.biomedcentral.com/1741-7007/9/42
Page 4 of 11Adding complexity to the culture environment
Eschenhagen  and  Zimmermann  [31]  have  pointed  out 
that  the  field  of  tissue  engineering  first  arose  as  a 
consequence of efforts to produce functional tissue for 
implantation. Over the past few years, many investigators 
have tried to apply the principles of tissue engineering to 
the  problem  of  producing  individual  types  of  differ  en­
tiated cells by making the cell culture environment more 
like  in  vivo  conditions,  essentially  by  making  it  more 
complex. Vunjak­Novakovic and Scadden [32] have sum­
marized the elements of a tissue engineering approach as 
including: (a) inducing factors; (b) extracellular matrix; 
(c) other cells, such as endothelial cells or stromal cells; 
and (d) physical factors, such as the rigidity of the tissue 
culture surface.
Various studies have incorporated some of these ele­
ments. As a simple start, numerous groups are interested 
in  growing  cells  as  three­dimensional  aggregates,  as  a 
kind of intermediate between standard culture conditions 
and the true in vivo setting. In essence, both embryoid 
bodies and neurospheres are based on this philosophy. 
Mei and colleagues [33] published a very extensive study 
in  which  ESCs  were  plated  on  a  combinatorial  set  of 
substrates and adsorbed proteins. They discovered a few 
combinations  that  supported  ESC  growth  and  colony 
formation  particularly  well.  Approaches  like  this  will 
undoubtedly prove useful, including as a way of replacing 
feeder  layers  or  for  encouraging  uniform  growth  and 
spreading  of  cells  across  the  culture  surface.  Underhill 
and  Bhatia  [34]  described  attempts  to  microfabricate 
extra  cellular matrix coated surfaces to allow cell growth, 
differentiation and survival. Several studies have empha­
sized the influence of the rigidity of the culture substrate. 
Gilbert and colleagues [35] found that muscle stem cells 
cultured on flexible hydrogel substrates like that found in 
real muscle retained more of their stem cell character­
istics  and  performed  better  in  a  muscle  regeneration 
assay. In another interesting application of tissue engi­
neering principles, Domian and colleagues [36] induced 
differentiation of cardiac progenitors, purified them by 
fluorescence­activated  cell  sorting  (FACS),  and  plated 
them  on  a  fabricated  thin  film,  thereby  constructing  a 
contractile sheet of cardiac muscle. These methods may 
turn out to be valuable in producing cells that are mature 
enough  to  adequately  represent  cellular  function  or 
dysfunction, as will be highlighted below.
A transdifferentiation approach
A recent promising alternative way of producing differen­
tiated cells, from large numbers of patients if necessary, is 
by  direct  reprogramming  —  or  transdifferentiation  — 
which  is  based  on  prior  identification  of  transcription 
factors important in lineage specification (Figure 1). Just 
a few years ago, Zhou and colleagues [37] showed that 
pancreatic exocrine cells could be converted in vivo to 
pancreatic  β­cells  by  infecting  them  with  adenovirus 
expressing  three  transcription  factors,  Ngn3,  Pdx1  and 
Mafa, all known to be important for β­cell development. 
Surprisingly,  this  occurred  without  proliferation  of  the 
exocrine  cells,  or  even  transient  dedifferentiation  to  a 
progenitor  cell  state.  Subsequently,  Vierbuchen  and 
colleagues  [38]  demonstrated  that  mouse  fibroblasts, 
following treatment with lentivirus containing genes for 
three  transcription  factors  expressed  in  the  nervous 
system,  Ascl1,  Brn2,  and  Myt1l,  could  be  induced  to 
differ  entiate directly to neurons. Neurons could also be 
derived from glial cells, which are embryologically more 
similar,  by  expression  of  only  Neurog2,  a  transcription 
factor important in neural determination [39]. Ieda and 
colleagues [40] showed that expressing three transcrip­
tion  factors  important  in  heart  development,  Gata4, 
Mef2c,  and  Tbx5,  could  cause  transdifferentiation  of 
fibroblasts into cardiac myocytes.
These  studies,  and  the  profusion  of  those  likely  to 
follow in the near future, demonstrate fibroblasts need 
not be dedifferentiated completely to become other cell 
types.  The  potential  advantage  of  this  more  direct 
approach, at least from a drug discovery perspective, is 
that  more  of  the  epigenetic  modifications  of  patient­
derived  cells  might  be  preserved  if  it  were  possible  to 
bypass  complete  reprogramming.  Also,  there  is  some 
hope  that  this  method  may  make  it  easier  to  produce 
more mature cells than one that relies on reversion of 
cells to a more embryonic cell­like state. Both of these 
differences  could  help  in  producing  cells  that  more 
accurately  model  components  of  different  diseases, 
although it is too early to judge how well the method will 
work. Can the fibroblasts be expanded sufficiently before 
viral  transduction  to  allow  for  the  generation  of  a 
sufficient number of differentiated cells? Can fibroblasts 
be  obtained  from  older  patients  and  still  be 
trans  differentiated?
A third possibility has arisen that is based on partial 
dedifferentiation  with  a  subsequent  differentiation  step 
(Figure 2). Reprogramming of mouse embryo fibroblasts 
is  initiated  but  then  aborted,  and  cells  are  put  into  a 
newly formulated medium that allows for the production 
of  (in  this  case)  cardiac  myocytes  [41].  Under  certain 
circumstances, this method might allow for sufficient and 
rapid expansion of a type of progenitor cell still capable 
of multilineage differentiation.
Small molecule regulators of differentiation
A final way of inducing cell differentiation is, in a sense, 
less  rigidly  adherent  to  the  notion  of  replicating  the 
precise inducing conditions that underlie in vivo develop­
ment. The thinking behind this is that most investigators 
interested in therapeutics have the production of a single 
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what happens during development, where the production 
of many different types of cells must be regulated in a 
synchronized  way  in  time  and  space.  This  raises  the 
possibility that it may be simpler to produce certain types 
of cells (perhaps all types of cells) in vitro by manipulating 
cells in entirely different ways from those that operate in 
vivo. This would be consistent with the above­mentioned 
studies  showing  that  cells  can  be  reprogrammed  by  a 
wide range of combinations of genes and small molecules.
The question is whether this is true of differentiation as 
well, and if so, how could these pathways be identified? 
We and many others have adopted a screening approach 
in  which  stem  or  progenitor  cells  are  treated  with 
hundreds or thousands of small molecules and the effects 
on  differentiation  measured,  generally  by  automated 
imaging.  As  reviewed  previously  [42],  certain  types  of 
small  molecule  libraries  are  useful  in  these  screens 
because, in principle, they allow for activation and in­
activation of many different intracellular signaling cascades. 
On  the  basis  of  this  idea,  Chen  and  colleagues  [43] 
followed the general format of sequential differentiation 
outlined in Figure 1, but, rather than restricting them­
selves to a small set of morphogens, tested about 5,000 
small molecules in a successful effort to find agents that 
increase the production of pancreatic progenitors from 
human endodermal cells. An extensive analysis of marker 
gene  expression  showed  that  the  chemically  induced 
progenitor  cells  were  highly  similar  to  the  ones  that 
appear in the embryo and were capable of progressing 
further through development, producing a small number 
of functional β­cells.
The most effective small molecule hits in this screen 
were  protein  kinase  C  (PKC)  activators.  It  will  be 
interesting  to  determine  if  PKC  activity  is  an  essential 
part of early pancreatic differentiation in vivo. Alterna­
tively,  PKC  might  be  a  crucial  component  of  an  alter­
native path from endoderm to pancreas that is not used 
in the embryo. Thus, manipulation of certain receptors or 
signaling pathways may allow cells to escape their rigid 
developmental  boundaries,  while  rendering  them  still 
capable of reaching a normal developmental endpoint. If 
Figure 2. Paths of cell differentiation. There are many paths from one differentiated cell to another. These include reprogramming to an iPSC 
followed by differentiation, transdifferentiation from one differentiated cell to another, and partial dedifferentiation to a cell that we call a PiPSC 
(partially induced pluripotent stem cell) followed by differentiation.
iPSC
PiPSC
Partial dedifferentiation
Transdifferentiation
Differentiated cell 1 Differentiated cell 2
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cations.  First  of  all,  it  raises  the  question  of  how  to 
establish  whether  the  cells  that  are  produced  by  the 
different methods are actually the same or at least similar 
enough. Recalling the discussion of pluripotency of ESCs 
and iPSCs, by many criteria, a variety of cell lines were 
classified as being pluripotent, but the standard criteria 
must have been too loose since the lines are variable. The 
same could be true with differentiated cells produced by 
different  methods,  so  it  may  be  necessary  to  use  an 
equivalent  of  the  scorecard  described  by  Bock  and 
colleagues [25]. Or, since there are, for the most part, two 
uses for differentiated cells — modeling disease in vitro 
and  functioning  appropriately  when  transplanted  —  it 
should be possible to establish practical criteria.
Disease modeling using stem cells: can stem cells 
help us find better and safer drugs?
Assuming that issues with the production of pluripotent 
cells from patients’ tissues, and the generation of differ­
entiated  cells  from  them,  can  be  resolved,  what  other 
con  cerns remain? Unfortunately, there are many funda­
mental questions that have still not been addressed.
One important issue relates to the degree of maturity of 
the cells that are produced. For instance, ALS and SMA 
are both motor neuron diseases, but they affect different 
motor neuron populations. In ALS, neurons innervating 
distal muscles are most sensitive while, in SMA, those 
innervating proximal muscles are most at risk. Further­
more, in both diseases certain rare populations of motor 
neurons  are  completely  unaffected  so,  in  theory,  when 
trying to model those diseases, using very specific types 
of  motor  neurons  would  be  most  appropriate.  In  fact, 
motor  neurons  produced  by  the  most  common  differ­
entiation protocols have a rather generic rostral cervical 
identity, although there is good reason to think that they 
can  be  induced  to  differentiate  further  by  additional 
morpho  gens  [44].  Presumably,  a  transdiffer  entiation 
approach  in  which  the  correct  motor  neuron  pool­
specific transcription factors are expressed in the motor 
neurons could also be successful.
This is not the only consideration, though. Typically, 
cells  derived  from  pluripotent  cells  resemble  their 
embryonic or immature counterparts (for example, [45]). 
Can they be induced to mature sufficiently to model adult 
disease? This has been hotly debated, especially in the 
context of late onset disease [46]. Many neurodegenera­
tive disorders, such as AD and PD, take decades to affect 
humans and even many months to affect transgenic mice, 
so  is  it  reasonable  to  think  that  neurons  derived  from 
stem cells could be induced to adopt a disease phenotype? 
It is possible that even in the late onset diseases, some of 
the  pathological  changes,  such  as  protein  aggregation, 
occur long before clinical symptoms. Another possibility 
relates  to  the  fact  that  many  of  these  diseases  are 
primarily sporadic and may be initiated by the presence 
of  particular  environmental  factors.  Exposing  cells  to 
high concentrations of, or prolonged incubation with, 
these factors might greatly accelerate the appearance of 
pathology in the cell culture environment. For example, 
the addition of cellular stressors, such as pro­oxidants 
or  other  compounds  that  compromise  mitochondrial 
func  tion,  might  bring  on  disease­related  alterations 
[45,46].
Another  important  issue  concerns  the  nature  of  the 
diseases that realistically can be modeled by applying a 
reprogramming or even a transdifferentiation method to 
patient­derived cells. Naturally, monogenic diseases seem 
most amenable to this technique, and monogenic diseases 
that affect predominantly one cell type are likely to be 
better still. For these conditions, the expectation is that 
the reprogramming process will maintain the mutations 
involved,  as  will  the  differentiation  protocol.  However, 
what about diseases that are mostly sporadic and might 
involve epigenetic modifications of the genome? In those 
cases, reprogramming would tend to erase most of the 
epigenetic marks. Perhaps the transdifferentiation method 
will help in this regard, but this is not yet clear.
Certainly, the major degenerative diseases of the nervous 
system are primarily late onset and, while mostly sporadic 
in nature, are known to involve a small percentage of cases 
with  well  known  disease­causing  mutations.  One  way 
forward  that  may  be  both  doable  and  instructive  is  to 
establish an in vitro phenotype using the genetic variants 
of  the  disease  first,  and  then  test  the  sporadic  cases  to 
determine if there are culture condi  tions that will produce 
the  same  disease  pathology.  Alterna  tively,  it  might  be 
possible  to  identify  pathology­producing  cell  culture 
manipulations that are informative about identifying the 
causative factors for the disease: for example, addition of 
certain  insecticides  may  accelerate  the  onset  of  disease 
features in a PD model [45].
Starting  just  a  few  years  ago,  there  have  been  many 
attempts  to  apply  an  overall  stem  cell  strategy  to  the 
understanding  of  specific  diseases.  The  typical  starting 
point has been the production of patient­specific iPSCs. 
One of the first comprehensive reports was that of Park 
and colleagues [47], who derived them from patients with 
adenosine deaminase deficiency­related severe combined 
immunodeficiency,  Shwachman­Bodian­Diamond  syn­
drome, Gaucher disease type III, Duchenne and Becker 
muscular dystrophy, PD, Huntington’s disease, juvenile­
onset diabetes, and Down syndrome/trisomy 21. More 
recent efforts have included production of iPSCs from 
patients  with  SMA  [48],  ALS  [49],  and  Hutchinson­
Gilford Progeria Syndrome (premature aging, associated 
with vascular defects) [50,51]. A few illustrative cases will 
be presented.
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One  of  the  first  examples  in  which  an  ESC­based 
approach (admittedly using mouse ESCs) contributed to 
a further understanding of disease mechanisms was that 
of ALS. Di Giorgio and colleagues [52] and Nagai and 
colleagues  [53]  established  in  vitro  models  of  ALS  by 
producing  motor  neurons  from  ESCs  isolated  from  a 
transgenic  mouse  that  carried  a  human  superoxide 
dismutase mutation (G93A) found in a small percentage 
of patients with ALS. Although ALS is a late onset disease 
(decades in humans; approximately 4 months in mice), 
the authors, nonetheless, found a disease phenotype — 
death of G93A­expressing motor neurons was faster than 
that  of  wild­type  motor  neurons.  In  addition,  they 
observed  that  astrocytes  in  the  G93A  motor  neuron 
cultures appeared to secrete a toxic factor that further 
accelerated motor neuron death. The effect was selective 
in  that  interneurons  were  not  killed  by  this  factor. 
Subsequent  work  by  Di  Giorgio  and  colleagues  [54] 
demon  strated that mutant mouse astrocyte­conditioned 
medium could also selectively kill human motor neurons 
produced  from  wild­type  human  ESCs.  Thus,  these 
investigators  succeeded  in  modeling  an  adult­onset 
neuro  degenerative  disease  and  in  gaining  some  insight 
into  molecular  mechanisms  that  underlie  the  disease. 
What remains uncertain is whether this conclusion can 
be generalized to other genetic forms of human ALS and 
whether it is possible to establish an informative disease 
phenotype starting with sporadic cases of ALS.
Another  interesting  recent  study  was  carried  out  by 
Marchetto  and  colleagues  [55].  Many  neurobiologists 
have been interested in using an iPSC­based approach to 
study  autism  spectrum  disorders  (ASDs),  a  group  of 
related neurodevelopmental defects. However, while there 
are undoubtedly genetic factors underlying these diseases, 
they  are  complex,  and  environmental  factors  seem  to 
play a major role. These investigators chose instead to 
investigate patients with Rett syndrome, which is asso­
ciated with impaired neural development about one year 
after birth and is caused by a mutation in the X­linked 
gene  MeCP-2.  Children  afflicted  with  Rett  syndrome 
have some of the symptoms found in other ASDs, but it is 
frequently  used  for  this  type  of  study  because  it  is  a 
genetic, rather than sporadic, disorder. This clearly makes 
it  amenable  to  an  iPSC  type  of  approach.  The  group 
produced iPSCs from patients and from them prepared a 
mixed  population  of  neurons,  including  GABA­ergic 
inhibitory neurons and glutamatergic excitatory neurons. 
Reassuringly, they found that the reprogramming process 
erased the X­inactivation of the MeCP-2 gene, but it was 
reestablished during neuronal differentiation, just as was 
hoped. Next, they found that there was not a large defect 
in survival of the induced neurons, at least after 2 months 
in culture. Nonetheless, there was a significant decease in 
the number of glutamatergic synapses, recapitulating the 
failure  to  appropriately  form  or  maintain  a  normal 
number of functional mature synapses seen in the syn­
drome.  Finally,  they  showed  that  insulin­like  growth 
factor  1  (IGF­1),  previously  shown  to  have  some 
ameliorative  effects  in  a  mouse  model  of  the  disease, 
could increase synapse number in these human cultures. 
Thus, the authors demonstrated the possibility of using 
an iPSC­based approach to gain an understanding of a 
complicated neural disorder and perhaps to screen for 
effective drugs.
Another good illustration of some of the points raised 
above  is  contained  in  a  study  on  PD,  a  major  neuro­
degenerative  disorder  affecting  a  subset  of  midbrain 
dopaminergic neurons [45]. Like ALS and AD, it is late­
onset  and  mostly  sporadic,  although  a  set  of  disease­
associated  mutations  has  been  identified,  the  most 
common of which is in the Leucine-rich repeat kinase-2 
(LRKK2)  gene.  To  model  the  disease,  Nguyen  and 
colleagues [45] derived iPSCs from patients with a LRKK2 
mutation.  They  then  followed  standard  protocols  to 
produce neuronal cultures that were not pure, but did 
contain dopaminergic neurons that were physiologically 
active. By microarray analysis, the neurons were similar 
to  those  found  in  human  fetal  brain.  Compared  to 
neurons produced from control patient iPSCs, they had 
high levels of expression of oxidative stress genes. They 
also  appeared  to  have  a  higher  level  of  the  protein  α­
synuclein, which forms characteristic aggregates in PD. 
Further, they seemed to be more susceptible to various 
stressors,  such  as  hydrogen  peroxide  and  6­hydroxy­
dopamine. Thus, although relatively immature, these iPS­
derived neurons were capable of modeling some aspects 
of  this  late  onset  disease.  Additional  studies  will  be 
needed to see how completely they reproduce the disease 
phenotypes, how reproducible these changes are when 
larger numbers of iPSC lines are tested and how other 
types of PD patient­derived iPSCs will behave.
Finally, a study illustrating many of the points raised in 
this  review  was  published  by  Lee  and  colleagues  [56]. 
These investigators were interested in familial dysauto­
nomia (FD), a genetic disorder associated with death of 
certain neural crest­derived neurons in sensory and auto­
nomic ganglia. The disorder is associated with a mutation 
of the IκB kinase complex-associated protein (IKBKAP) 
gene, resulting in a splicing defect and reduced level of 
full­length IKAP protein. Fibroblasts were obtained from 
one young girl with FD and used to prepare iPSCs that 
were then induced to differentiate into different types of 
cells. Neural crest precursors showed a particularly low 
level  of  intact  IKAP  protein  and  had  clear  defects  in 
migra  tion and neuronal differentiation. Lee and colleagues 
further showed that kinetin, a plant hormone known to 
be effective when tested on lymphoblastoid cells from an 
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crest  precursors.  This  sets  the  stage  for  a  more 
comprehensive drug screen using iPSC­derived cells.
Cardiovascular disease and drug toxicity testing
Several  interesting  studies  relate  to  cardiac  myocytes 
made from reprogrammed cells. Itzhaki et al. [57] pro­
duced cardiac myocytes from iPSCs isolated from patients 
that have a K+ channel mutation found in congenital long 
QT syndrome (LQTS), a disorder associated with cardiac 
arrhythmias.  The  myocytes  also  had  increased  action 
potential duration, and the authors were able to screen 
different pharmacological agents to see which ones could 
correct  the  underlying  electrophysiological  defect.  In 
another  study,  Carvajal­Vergara  and  colleagues  [58] 
pursued a very interesting and presumably rare disorder 
known as LEOPARD syndrome. It is characterized most 
frequently by hypertrophic cardiomyopathy and is caused 
by mutations in the gene (PTPN11) that codes for the 
phosphatase  SHP2.  Interestingly,  iPSC­derived  cardiac 
myocytes  from  patients  were  larger  than  those  from 
controls, and the group has begun to dissect abnormal 
signaling within these cells that might be abrogated to 
ameliorate  the  disease  phenotype.  This  is  the  kind  of 
study,  carried  out  in  a  rare  disease  background,  that 
could contribute more generally to our understanding of 
other, more common types of cardiomyopathy.
The other widely discussed use for iPSC technology is 
in  producing  cardiac  myocytes  and  hepatocytes  to 
facilitate preclinical human testing of drug side effects. 
To date, much more progress has been made in produc­
ing cardiac cells. Braam and colleagues [59] carried out 
an early study using human ESCs as a source of human 
cardiac myocytes. They tested about 12 drugs that were 
already  known  either  to  affect  or  not  to  affect  cardiac 
cells in patients. Similar activities were reproduced in the 
stem  cell  derived  cultures.  This  is  the  beginning  of 
toxicity studies that, in the future, should be done in the 
predictive sense: testing drugs on patient­derived cardiac 
cells before it is known how they will affect the patients. 
It  will  be  especially  important  to  decide  how  many 
patients’ cells need to be tested to establish a sufficiently 
Figure 3. A schematic diagram of a possible approach to using a stem cell-based system in a drug discovery campaign. The central idea is 
that the cells used for screening, efficacy and safety testing would be patient-derived. Also, lines of cells, potentially prepared from many patients, 
would be used for efficacy and safety testing in vitro prior to testing on those patients in vivo. It is hoped that this will increase the probability of 
clinical success.
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drug  will  have  cardiac  toxicity  and,  even  more 
importantly, to help to identify biomarkers for sensitive 
and insensitive patients.
Prospects for the future
There  seems  to  be  a  widely  held  belief  that  the  drug 
discovery system, as generally used in the pharmaceutical 
industry, needs to be improved, perhaps radically. In this 
article, we have suggested that a stem cell­based program 
might do just that by providing human disease­relevant 
cells in numbers large enough to be used to: discover new 
pathologies,  thereby  establishing  better  drug  targets; 
carry out more predictive primary and secondary screen­
ing  assays;  test  drug  safety;  and  identify  subsets  of 
patients most likely to respond to particular therapeutic 
classes. This is summarized in Figure 3.
Much work needs to be done before we can be certain 
that  differentiated  cells  produced  from  patient­derived 
iPSCs will offer any dramatic advantages. At present, we 
are uncertain whether the process of reprogramming, so 
essential  to  this  method,  is  fundamentally  flawed.  Our 
view is that there will be many technical improvements 
over  the  next  few  years  in  the  method  of  producing 
patient­specific  differentiated  cells  (via  reprogramming, 
transdifferentiation or partial reprogramming) to allow all 
of the relevant studies to be executed. A greater under­
standing  will  also  be  achieved  with  respect  to  the 
reproducibility of the process. At present, we do not know 
even how many iPSC clones per individual patient need to 
be produced to provide adequate consistency, nor do we 
know the true variability in response among cells derived 
from many patients with the same genetic disorder.
A final question that can be raised from the many types 
of in vitro studies described here relates to the seemingly 
ephemeral nature of the differentiated state. Why is it so 
relatively easy to change one type of cell into a radically 
different one? Does this suggest that cell identity could be 
changing, to at least some degree, much of the time? Does 
the  existence  of  metaplastic  cells  also  suggest  the 
possibility  that  this  phenomenon  can  occur  without 
external manipulation? If so, does it further suggest the 
possibility that this process can be mobilized for thera­
peutic purposes? Will it be possible to interconvert cells 
using drugs — for instance, making muscle out of fat or 
connective tissue, or neurons out of glia — as an entirely 
different way of treating degenerative disorders or diseases 
of aging? If nothing else, new biological concepts derived 
from  studying  stem  cell  behavior  may  contribute  to 
completely novel modes of treatment for serious diseases.
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